Antimicrobial activity and clinical efficacy of teicoplanin

• Published in: CHEMOTHERAPY Vol. 41; no. Supplement2; pp. 242 - 245
• Main Authors: Kurimura, Osamu, Koda, Tetsuzo, Ichimura, Hiroshi, Tamura, Ikuo, Hiramoto, Takehiko, Nakano, Kikuo, Takeda, Kouji, Tominaga, Naoko, Nozaki, Kimitoshi, Doi, Hideyuki, Kono, Michiko, Shimonaka, Akiko, Kondo, Mitsuko, Maruyama, Taisuke, Furui, Jun
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1993
• Subjects: Teicoplanin
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.41.Supplement2_242

The antimicrobial activity of teicoplanin (TEIC) was measured against clinically isolated strains of Staphylococcus aureus containing methicillin-resistant S. aureus (MRSA), coagulasenegative staphylococci (CNS), Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Enterococcus faecalis and Corynebacterium spp. The activity of the drug was compared with those of vancomycin (VCM), arbekacin (ABK), minocycline (MINO) and rifampicin (RFP) against Staphylococcus spp. The activities of cefazolin (CEZ) and ofloxacin (OFLX) were also measured against MRSA. Against S. aureus containing MRSA, TEIC showed almost the same activity as VCM, and no resistant strain was observed. Although RFP showed the most powerful activity among the drugs, some strains resisted it. ABK-, MINO-and OFLXresistant strains were found. Some strains of CNS resisted TEIC. The activity of TEIC was excellent against Streptococcus spp., E. faecalis and Corynebacterium spp. TEIC was administered to two patients with staphylococcal septicemia, and clinical responses were good in one case and fair in the other. As to bacteriological efficacy, the isolate was eradicated in the case with the good result. No adverse reaction was observed in either case in spite of their severe underlying diseases.